|
gptkbp:instanceOf
|
gptkb:drug
antimuscarinic agent
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:ATCCode
|
G04BD08
|
|
gptkbp:brand
|
gptkb:Vesicare
|
|
gptkbp:CASNumber
|
242478-38-2
|
|
gptkbp:chemicalFormula
|
C23H26N2O2
|
|
gptkbp:contraindication
|
urinary retention
uncontrolled narrow-angle glaucoma
gastric retention
|
|
gptkbp:developer
|
gptkb:Astellas_Pharma
|
|
gptkbp:eliminationHalfLife
|
45-68 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
solifenacin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
362.47 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
blurred vision
QT prolongation
dry mouth
urinary retention
|
|
gptkbp:synonym
|
gptkb:YM905
gptkb:solifenacin_succinate
|
|
gptkbp:usedFor
|
urinary incontinence
overactive bladder
urinary frequency
urinary urgency
|
|
gptkbp:bfsParent
|
gptkb:Vesicare
|
|
gptkbp:bfsLayer
|
6
|